Gufic Biosciences: Intimation regarding USFDA Pre-Approval Inspection at the Company's Manufacturing facility situated at…
Gufic Biosciences (GUFICBIO) filed a disclosure titled "Intimation regarding USFDA Pre-Approval Inspection at the Company's Manufacturing facility situated at Indore, Madhya Pradesh is attached herewith". The company is valued at about ₹3,906 crore.
What happened
Gufic Biosciences (GUFICBIO) filed a disclosure with the exchanges on 23 October 2026 at 08:41 PM titled "Intimation regarding USFDA Pre-Approval Inspection at the Company's Manufacturing facility situated at Indore, Madhya Pradesh is attached herewith".
Company snapshot
Gufic Biosciences is a small-cap company, with a market value of about ₹3,906 crore.
The stock last traded at ₹389.5, against a 52-week range of ₹268–₹467.8 (16.7% below the high).
Before this filing the shares had moved −10.7% over the month and −1.8% over three months. Average daily turnover over the last 20 sessions was about ₹3.75 crore.
Promoters held 72.50% at the end of Q1 FY27. Foreign institutions owned 0.46% and domestic institutions 3.68%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 224 | 13.1 | 1.3 |
| Q2 FY26 | 237 | 16.8 | 1.68 |
| Q3 FY26 | 231 | 12.4 | 1.24 |
| Q4 FY26 | 252 | 21.9 | 2.18 |
| Q1 FY27 | 261 | 22.3 | 2.22 |
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,516 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.